Octreotide Acetate

CHEMBL1200480 Phase 4 Aprobado Protein

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

1139.3 g/mol

LogP

—

Phase

4

A acetate salt form of octreotide with the same therapeutic properties. A synthetic somatostatin that suppresses hormone release from tumors, used for carcinoid tumors and acromegaly.

Peso molecular

1139,3000 g/mol

TPSA

457,00 Å²

Áreas terapéuticas

Cáncer colorrectal Cáncer de mama Cáncer de ovario Cáncer de páncreas Cáncer de próstata Cáncer de pulmón de células no pequeñas Cáncer de tiroides Cáncer de vejiga Diabetes tipo 2 Enfermedad cardiovascular Enfermedad del hígado graso no alcohólico Hipertensión Ictus Linfoma Melanoma Migraña Obesidad

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Estructura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CC(=O)O.C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O

InChI

InChI=1S/C49H66N10O10S2.C2H4O2/c1-28(61)39(25-60)56-48(68)41-27-71-70-26-40(57-43(63)34(51)21-30-13-5-3-6-14-30)47(67)54-37(22-31-15-7-4-8-16-31)45(65)55-38(23-32-24-52-35-18-10-9-17-33(32)35)46(66)53-36(19-11-12-20-50)44(64)59-42(29(2)62)49(69)58-41;1-2(3)4/h3-10,13-18,24,28-29,34,36-42,52,60-62H,11-12,19-23,25-27,50-51H2,1-2H3,(H,53,66)(H,54,67)(H,55,65)(H,56,68)(H,57,63)(H,58,69)(H,59,64);1H3,(H,3,4)/t28-,29-,34-,36+,37+,38-,39-,40+,41+,42+;/m1./s1

Molecular Formula

C53H74N10O14S2

HBD / HBA

15 / 18

Enlaces Rotables

17

Átomos Pesados

79

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

A acetate salt form of octreotide with the same therapeutic properties. A synthetic somatostatin that suppresses hormone release from tumors, used for carcinoid tumors and acromegaly.

Yes, Octreotide Acetate is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200480. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 155804637. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

¿Busca información accesible para el paciente?

Octreotide Acetate en PillFYI

Estructura

Datos Rápidos

Fórmula: C53H74N10O14S2
Sinónimos: 4

Enlaces externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.